The pathophysiological role of the neurosteroid 3a-hydroxy-5a-pregnan-20-one (allopregnanolone) in neuropsychiatric disorders has been highlighted in several recent investigations. For instance, allopregnanolone levels are decreased in the CSF of patients with post-traumatic stress disorder (PTSD) and major unipolar depression. Neurosteroidogenic antidepressants, including fluoxetine and analogs, correct this decrease in a manner that correlates with improved depressive symptoms. PTSD-like behavioral dysfunctions, including heightened aggression, exaggerated fear, and anxiety-like behavior associated with a decrease in corticolimbic allopregnanolone content are modeled in mice by protracted social isolation stress. Allopregnanolone is not only synthesized by principal glutamatergic and c-aminobutyric acid (GABA)ergic neurons, but also locally, potently, positively, and allosterically modulates GABA action at postsynaptic and extrasynaptic GABA A receptors. Hence, this paper will review preclinical studies, which show that in socially isolated mice, rather than selective serotonin reuptake inhibitor mechanisms, allopregnanolone biosynthesis in glutamatergic corticolimbic neurons offers a nontraditional target for fluoxetine to decrease signs of aggression, normalize fear responses, and decrease anxiety-like behavior. At low selective serotonin reuptake inhibitorinactive doses, fluoxetine and related congeners potently increase allopregnanolone levels by acting as potent selective brain steroidogenic stimulants (SBSS), thereby facilitating GABA A receptor neurotransmission and improving behavioral dysfunctions. Although the precise molecular mechanisms that underlie the action of these drugs are not fully understood, findings from socially isolated mice may ultimately generate insights into novel drug targets for the treatment of psychiatric disorders, such as anxiety and panic disorders, depression, and PTSD.
Introduction
For almost half a century, it has been proposed that serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition is the main molecular mechanism responsible for the anxiolytic, antipanic, antidysphoric, and antidepressant action of selective serotonin reuptake inhibitors (SSRIs) (Bunney and Davis, 1965; Schildkraut, 1965; Wong et al., 1993; Mongeau et al., 1997; Hirschfeld, 2000; Burke, 2004) . However, several reports have argued with this hypothesis and in recent years, studies have suggested that the so called 'SSRI antidepressants' may exert their therapeutic actions by interacting on other neurochemical parameters unrelated to their intrinsic selective 5-HT reuptake inhibitory activity (Nestler et al., 2002; Santarelli et al., 2003; Castrén, 2005; Aboukhatwa and Undieh, 2010; Castrén and Rantamäki, 2010; Castro et al., 2010) .
The observation that a single dose of fluoxetine and paroxetine potently, dose dependently, and region selectively increase the content of the g-aminobutyric acid A (GABA A ) receptor-active neurosteroid allopregnanolone in various brain areas (olfactory bulb > frontal cortex > hippocampus > cerebellum > striatum) of adrenelectomized/castrated rats, led to the suggestion that an increase of brain allopregnanolone content may be part of the mechanism for the pharmacological actions of SSRIs (Uzunov et al., 1996; Guidotti and Costa, 1998) . Furthermore, fluoxetine and paroxetine selectively increased the levels of allopregnanolone, but not those of the immediate precursor of allopregnanolone, 5a-dihydroprogesterone (5a-DHP) and also failed to change the levels of allopregnanolone in plasma, which suggests a specific brain-operated mechanism for fluoxetine that may be independent of peripheral steroid renovation sources (Uzunov et al., 1996) .
Meanwhile, a role for CSF or serum allopregnanolone levels has been reported in several psychiatric conditions, ranging from postpartum depression and premenstrual dysphoria to schizophrenia and anxiety-related spectrum disorders, including panic and post-traumatic stress disorders (PTSD), and major depression (Rapkin et al., 1997; Bloch et al., 2000; Nappi et al., 2001; Ströhle et al., 2002; Backstrom et al., 2003; Amin et al., 2006; Rasmusson et al., 2006; Marx et al., 2009; Pearlstein, 2010) .
In PTSD, the CSF levels of allopregnanolone, 5a-DHP, dehydroepiandrosterone (DHEA -a negative modulator of GABA A receptor function), and progesterone were measured in premenopausal women with and without PTSD (Rasmusson et al., 2006) . There were no group differences in progesterone, 5a-DHP, or DHEA levels, whereas the CSF levels of allopregnanolone were 40 fmol/ ml in non-PTSD subjects, the PTSD group allopregnanolone levels were approximately 40% of healthy group levels (Rasmusson et al., 2006) . This allopregnanolone/ DHEA ratio correlated negatively with PTSD reexperiencing symptoms and with Profile of Mood State Depression/Dejection scores. These results suggest that low CSF allopregnanolone levels in premenopausal women with PTSD may contribute to an imbalance in inhibitory versus excitatory neurotransmission resulting in increased PTSD re-experiencing and depressive symptoms (Rasmusson et al., 2006) . Of note, this study also reported that allopregnanolone levels, which decreased in the whole PTSD group, reached their lowest levels in patients with PTSD and comorbid depression (Rasmusson et al., 2006) .
The concept that an increase of allopregnanolone bioavailability contributes to the anxiolytic and antidepressant actions of fluoxetine, and other SSRIs is supported by the observation that allopregnanolone levels, measured in four cisternal-lumbar fractions in the CSF before and 8-10 weeks after treatment with fluoxetine or fluvoxamine in 15 patients with unipolar major depression, were about 60% lower (approximately 15 fmol/ml) in patients with major depression (Uzunova et al., 1998) . However, in the same patients, treatment with fluoxetine or fluvoxamine normalized CSF allopregnanolone content to control values (approximately 40 fmol/ml). Moreover, a statistically significant correlation existed between symptomatology improvement (Hamilton Rating Scale for Depression scores) and the increase in CSF allopregnanolone after fluoxetine or fluvoxamine treatment (Uzunova et al., 1998) . The CSF content of pregnenolone and progesterone remained unaltered after SSRI treatment and failed to correlate with the fluoxetine or fluvoxamine-induced increase of CSF allopregnanolone levels (Uzunova et al., 1998) . The normalization of CSF allopregnanolone content in depressed patients seemed to be sufficient to mediate the anxiolytic and antidysphoric actions of fluoxetine or fluvoxamine through its positive allosteric modulation of GABA A receptors (Uzunova et al., 1998) .
This pioneering discovery of Uzunova and colleagues (1998) remains one of the best-reported investigations in the field of neurosteroids and psychiatric disorders for a number of reasons. For instance, allopregnanolone levels were measured in the CSF, rather than in the serum, which may not reflect allopregnanolone biosynthesis occurring in the brain. Further, the levels of CSF allopregnanolone in normal subjects and unipolar depressed patients were correlated with each patient's behavioral symptoms. Most importantly, this investigation reported a correlation between the levels of CSF allopregnanolone and behavioral symptoms pretreatment and post-treatment with fluoxetine and fluvoxamine (Uzunova et al., 1998) . A number of other investigations confirmed Uzunova's findings in the serum of depressed patients after antidepressant therapy (Romeo et al., 1998; reviewed in Pisu and Serra, 2004; Eser et al., 2006; Uzunova et al., 2006; Longone et al., 2008 ).
The clinical data described above led to the hypothesis that decreased CSF levels of allopregnanolone could reflect a dysfunction of the rate-limiting step-enzyme of allopregnanolone biosynthesis, 5a-reductase type I (5a-RI) in a patient's corticolimbic structures. Thus, a study was carried out to evaluate the expression of 5a-RI mRNA in prefrontal cortical area BA9, and cerebellum from depressed patients that were age-matched and sexmatched with nonpsychiatric subjects (Agis-Balboa et al., 2010) . In depressed patients, the mRNA expression levels of 5a-RI were strongly decreased compared with those of normal subjects (Agis-Balboa et al., 2010) . In contrast, 5a-RI failed to change in the cerebellum of depressed patients (Agis-Balboa et al., 2010).
Mood disorders, including anxiety and fear, can be modeled in mice to study anxiolytic and antidepressant drugs. This paper reviews preclinical studies in animal models of anxiety-like behavior, including PTSD, which suggest that fluoxetine and congeners exert pharmacological effects through stimulation of neurosteroid biosynthesis rather than by inhibiting 5-HT reuptake.
Role of neurosteroids as endogenous modulators of GABA A receptors
In the central nervous system, neurosteroids are synthesized independently from peripheral sources (adrenals and testes) (Baulieu, 1981; Cheney et al., 1995; Baulieu et al., 2001; Guidotti et al., 2001; Stoffel-Wagner, 2001 ). Hence, the term 'neurosteroid' is applied to those steroids that are specifically synthesized in the brain, where they reach physiological significant levels to modulate gene expression and neurotransmitter systems (Puia et al., 1990 (Puia et al., , 1991 (Puia et al., , 2003 Majewska, 1992; Pinna et al., 2000; Lambert et al., 2003 Lambert et al., , 2009 Belelli and Lambert, 2005) . Several pharmacological studies have indicated that allopregnanolone expresses anticonvulsant, anxiolytic, antidepressant, and even sedative-hypnotic actions (Jain et al., 2005; Martin-Garcia and Pallares, 2005; Mares et al., 2006; Lonsdale and Burnham, 2007; Kita and Furukawa, 2008; Nin et al., 2008; Rodríguez-Landa et al., 2009; D'Aquila et al., 2010) . These effects resemble those elicited by several positive allosteric modulators of GABA action at GABA A receptors, including barbiturates and benzodiazepines (Majewska, 1992; Guidotti et al., 2001) , and thus, these effects define allopregnanolone as a 'neuroactive steroid'. This review will focus on allopregnanolone, which is produced widely in several brain areas from progesterone metabolism (Pinna et al., 2000; Dong et al., 2001) . As indicated in Fig. 1 , progesterone is metabolized by the sequential action of two enzymes, 5a-RI, which transforms progesterone into 5a-DHP, and 3a-hydroxysteroid dehydrogenase (3a-HSD), which reduces 5a-DHP to allopregnanolone in a reversible manner.
The distribution and the content of 5a-DHP and allopregnanolone in various brain regions is not uniform (Pinna et al., 2000; Dong et al., 2001; Pibiri et al., 2008) . In rodents, the olfactory bulb shows the highest concentrations of 5a-DHP and allopregnanolone, followed by the frontal cortex, hippocampus, amygdala, striatum, and cerebellum . 5a-DHP exerts a genomic action and interacts with high affinity with the intracellular progesterone receptors (Rupprecht and Holsboer, 1999) . In contrast, allopregnanolone acts as a potent (nmol/l affinity) positive allosteric modulator of the action of GABA at GABA A receptors, where it potentiates the intensity of GABA-gated Cl -currents (Puia et al., 1990 (Puia et al., , 1991 (Puia et al., , 2003 Lambert et al., 2003 Lambert et al., , 2009 ). The physiological relevance of endogenous allopregnanolone is substantiated by the finding that this neurosteroid not only potentiates the inhibitory signals resulting from the release of GABA acting on GABA A receptors, but also plays a facilitatory permissive role in fine tuning the efficacy of direct receptor activators such as muscimol or that of other positive allosteric modulators of GABA action at GABA A receptors, including benzodiazepines and barbiturates (Matsumoto et al., 1999 Pinna et al., 2000; Guidotti et al., 2001; Puia et al., 2003) .
Two discrete binding sites in the transmembrane domains of the GABA A receptor that mediate the potentiation and direct activation effects of allopregnanolone have recently been identified (Hosie et al., 2006) . This study, for the first time, has clarified that allopregnanolone potentiates GABA responses from a cavity formed by the a-subunit transmembrane domains, whereas direct receptor activation is initiated by interfacial residues between the a and b subunits (Hosie et al., 2006) . GABA A receptor activation is greatly enhanced when allopregnanolone binds to the potentiation site (Hosie et al., 2006) . These authors show that significant receptor activation by allopregnanolone relies on occupancy of both the activation and potentiation sites (Hosie et al., 2006) . The identification of these sites, which are highly conserved throughout the GABA A receptor family, opens new avenues for neurosteroid pharmacological studies.
Recent studies reported that GABA A receptors incorporating a4, a6, and d subunits in combination with g and b subunits may have a higher affinity for neurosteroids than other recombinant GABA A receptor subtypes that express different subunit combinations (Belelli et al., 2002; Belelli and Lambert, 2005) . However, the affinity of neurosteroids for these GABA A receptor subtypes remains in the low range (Puia et al., 1990 (Puia et al., , 1991 . Thus, neurosteroid allosteric positive modulators of the action 
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of GABA at GABA A receptors show a pharmacological profile much less differentiated than that of the GABA A receptor modulation by benzodiazepines, which have low-intrinsic activity at GABA A receptor-containing a4 or a6 subunits (Puia et al., 1990 (Puia et al., , 1991 Vicini, 1991; Costa and Guidotti, 1996) .
In corticolimbic circuit neurons, local neurosteroid bioavailability modulates GABA A receptors
A recent immunohistochemistry study has clarified the neuronal localization of the neurosteroidogenic enzymes 5a-RI and 3a-HSD, and has provided a new understanding of how allopregnanolone is produced in neurons and is secreted locally to reach and activate postsynaptic and extrasynaptic GABA A receptors (Fig. 2) .
The enzymes 5a-RI and 3a-HSD were shown to be highly expressed and to co-localize in a region-specific way in primary GABAergic and glutamatergic output neurons, including pyramidal neurons, granular cells, reticulo-thalamic neurons, medium spiny striatum and nucleus accumbens neurons, and Purkinje neurons, but are virtually absent in GABAergic cortical interneurons and glial cells (Agis-Balboa et al., 2006).
Long projecting primary GABAergic neurons located in the reticular thalamic nucleus, which express high levels of 5a-RI and 3a-HSD, are likely to secrete allopregnanolone at the time when they release GABA to target postsynaptic GABA A receptors incorporated in dendrites and somata of glutamatergic thalamocortical neurons (Pinault, 2004) . Similarly, it is suggested that allopregnanolone synthesized by medium spiny GABAergic striatal neurons, and allopregnanolone that is produced by cerebellum Purkinje cells, may activate postsynaptic GABA A receptors located on cell bodies or dendrites of neurons in deep cerebellar nuclei (Agis-Balboa et al., 2006).
Allopregnanolone synthesized in glutamatergic cortical or hippocampal pyramidal neurons or in granular cells of the dentate gyrus may be secreted in a paracrine fashion to reach distal GABA A receptors inserted in cell bodies or dendrites of cortical or hippocampal pyramidal neurons ( Fig. 2 ). In addition, allopregnanolone may act locally by reaching postsynaptic or extrasynaptic GABA A receptors located on the same dendrites or cell bodies of the cortical or hippocampal pyramidal neuron itself that has produced allopregnanolone (Agis-Balboa et al., 2006). Finally, allopregnanolone might not be released, but may access GABA A receptors located on the cell bodies Physiological levels of allopregnanolone maintain the function of g-aminobutyric acid (GABA)ergic neurotransmission in the brain (Pinna et al., 2000) . This diagrammatic representation depicts the local action of allopregnanolone on GABA A receptors located on synaptic membranes of pyramidal neurons. GABA released from GABAergic interneurons activates a family of postsynaptic and extrasynaptic GABA A receptors. Allopregnanolone may facilitate the synaptic inhibitory action of GABA at postsynaptic and extrasynaptic GABA A receptors by an autocrine mechanism (arrow 1) (Agis-Balboa et al., 2006) or may access GABA A receptors by acting at the intracellular sites (arrow 2) (Akk et al., 2005) of the GABA A receptors.
or dendritic arborization of glutamatergic neurons acting at the intracellular sites of the GABA A receptors by lateral diffusion into plasma membranes (Akk et al., 2005; Agis-Balboa et al., 2006) (Fig. 2) .
The modality of local allopregnanolone region-and neuronspecific biosynthesis and release and its action on GABA A receptors suggest that this neurosteroid may not only ensure a proper activation of GABA A receptors in physiological conditions but at the same time may represent a biomarker that can be targeted in psychiatric disorders characterized by a dysfunction of GABAergic neurotransmission.
Role of allopregnanolone in the regulation of aggressive behavior, anxiety, and excessive fear induced in mice by social isolation
Allopregnanolone has emerged as an important regulator of behavioral deficits induced in rodent models of depression and anxiety spectrum disorders (Uzunova et al., 2004; Pibiri et al., 2008) .
In the author's laboratory, a mouse model characterized by a downregulation of allopregnanolone biosynthesis, induced by a protracted social isolation stress, has been adopted to establish the fundamental role of allopregnanolone in the regulation of contextual fear, anxiety-like behavior, and aggression (Matsumoto et al., 1999; Dong et al., 2001; Pinna et al., 2003a Pinna et al., , 2006a Agis-Balboa et al., 2007; Pibiri et al., 2008) (Nelson M and Pinna G, in press ). In male mice socially isolated for a period of 4 weeks, we have earlier shown a time-dependent increase of aggressive behavior at the same time that corticolimbic allopregnanolone levels were decreased (Pinna et al., 2003a) . Similarly, using Pavlonian fear conditioning, during which mice were exposed to a novel environment (i.e. the context) for the administration of an acoustic tone (the conditionined stimulus) and the unconditioned stimulus of a footshock, mice exhibited a conditioned fear response comprising enhanced freezing time 24 h after the training section Pinna et al., 2008) . In socially isolated mice, there was a time-related increase of contextual fear-conditioning responses that was inversely correlated with the decay of 5a-RI expression determined in the hippocampus and amygdala . Fear-conditioning responses, similar to aggressive behavior, increased during the 4 weeks and a plateau was reached between 4 and 8 weeks of social isolation (Pinna et al., 2003a; Pibiri et al., 2008) . In a fearconditioning extinction trial, freezing time declined rapidly over the first 3 days, during which mice were repeatedly exposed to the context chamber; however, the socially isolated mice showed: (i) higher levels of contextual freezing time on day 1 of exposure to the chamber and (ii) a delayed extinction. The contextual fear extinction in socially isolated mice failed to reach the low values of the group-housed control mice, suggesting that in socially isolated mice, fear extinction is not only delayed, but also incomplete . In accord with these results, we had earlier shown that socially isolated mice exhibited higher levels of anxiety-like behaviors, determined in the elevated plus maze and in the open field (Pinna et al., 2006a) .
Evidence collected in our laboratory supports the concept that corticolimbic allopregnanolone plays a pivotal role in the regulation of contextual fear conditioning and aggression (Pinna et al., 2003a (Pinna et al., , 2006a Pibiri et al., 2008) (Nelson M and Pinna G, in press) . Hence, as a proof of concept, experiments were undertaken, which showed that administration of allopregnanolone dose dependently attenuates the duration of attacks toward a male intruder (Pinna et al., 2003a (Pinna et al., , 2006a . The attenuation of aggression is accompanied by an upregulation of cortico-limbic allopregnanolone content (Pinna et al., 2003a (Pinna et al., , 2006a Matsumoto et al., 2007) . Similarly, single injections of allopregnanolone normalized the exaggerated contextual fear responses expressed by socially isolated mice .
Other groups have shown that allopregnanolone elicits antianxiety properties (Bitran et al., 1991; Wieland et al., 1991; Rodgers and Jonhson, 1998; Frye and Rhodes, 2006) when administered systemically or by direct infusion into target corticolimbic areas, including the basolateral amygdala, central amygdala, hippocampus, and prefrontal cortex (Nelson M and Pinna G, in press) (Engin and Treit, 2007; Deo, et al., 2010) . In addition, inhibiting allopregnanolone biosynthesis in the midbrain ventral tegmental area has been shown to reduce the antianxiety properties of allopregnanolone, an action which can be reversed by administering neurosteroidogenic drugs, including FGIN 1-27 (Frye et al., 2009) .
A brain region-specific downregulation of 5a-RI in socially isolated mice has been revealed by the application of RT-PCR and in-situ hybridization to determine the expression levels of 5a-RI in various brain structures that include neurons with intense neurosteroidogenesis Pibiri et al., 2008) . The highest decrease of 5a-RI was found in the amygdala and hippocampus, followed by the olfactory bulb and the frontal cortex . In contrast, the expression of 5a-RI failed to change in the cerebellum and striatum . Similarly, using gas chromatography-mass fragmentography to detect picomolar amounts of allopregnanolone in discrete brain structures, we confirmed that the decrease of 5a-RI in the above-mentioned brain areas resulted in a massive reduction of the levels of allopregnanolone . In-situ immunohistochemical studies conducted in socially isolated and group-housed mice have shown that 5a-RI is specifically decreased in cortical pyramidal neurons of layers V-VI, in hippocampal CA3 pyramidal neurons and glutamatergic granular cells of the dentate gyrus, and in the pyramidal-like neurons of the basolateral amygdala . However, 5a-RI fails to change in primary GABAergic neurons of the reticular thalamic nucleus, central amygdala, cerebellum, and in the medium spiny neurons of the caudatus and putamen .
To examine the hypothesis that cortico-limbic allopregnanolone level downregulation is responsible for the aggressive behavior and enhanced conditioned fear responses found in socially isolated mice, we administered the potent 5a-RI competitive inhibitor SKF 105 111 to normal group-housed mice (Cheney et al., 1995; Pinna et al., 2000 Pinna et al., , 2008 . SKF 105 111 rapidly (approximately 1 h) decreased the level of allopregnanolone in the olfactory bulb, frontal cortex, hippocampus, and amygdala to 80% of their original levels Pinna et al., 2008) . This decrease of allopregnanolone is maintained up to 6 h and results in a downregulation of GABA A receptor responsiveness to direct receptor activators or positive allosteric modulators of GABA action at GABA A receptors, including pentobarbital, muscimol, ethanol, and benzodiazepine, or to GABA A receptor antagonists such as picrotoxin (Matsumoto et al., 1999; Pinna et al., 2000; Guidotti et al., 2001; Matsumoto et al., 2003) .
Consistent with the above-mentioned results, administration of SKF 105 111 2 h before contextual fear-conditioning training induced a dose-dependent increase of contextual fear-conditioning responses that negatively correlated with depletion of hippocampal allopregnanolone level . The effects of SKF 105 111 on contextual fear responses were reversed by administering allopregnanolone doses that normalized hippocampus allopregnanolone levels .
Protracted social isolation in mice as a mouse model relevant for post-traumatic stress disorder
Several behavioral and neurochemical alterations that are commonly found in PTSD patients can be reproduced by protracted social isolation in mice.
First, a downregulation of the CSF levels of allopregnanolone that correlates with negative re-experiencing symptoms was shown in PTSD premenopausal women with comorbid depressive symptoms (Rasmusson et al., 2006) . Socially isolated mice express a downregulation of corticolimbic allopregnanolone levels in pivotal regions for the regulation of emotional behaviors, including the medial frontal cortex, hippocampus, and the basolateral amygdala Second, the expression of impulsive aggression and violence is heightened in combat veterans (Forbes et al., 2008) . Accordingly, one of the best-characterized behavioral deficits of socially isolated mice are the very high levels of aggression (Garattini et al., 1967; Valzelli, 1981 Further, in PTSD patients, there were enhanced contextual fear-conditioning responses, and impaired extinction of fear was evident when these patients were re-exposed to the events that symbolize the triggering traumatic event; however, cued fear conditioning was not changed (Grillon and Morgan, 1999; Ameli and Grillon, 2001; Rauch et al., 2006) . Socially isolated mice analogously display exaggerated contextual fear conditioning and delayed and incomplete fear extinction with unchanged cued fear conditioning .
Finally, PTSD patients fail to respond to the anxiolytic and sedative properties of benzodiazepines (Gelpin et al., 1996; Viola et al., 1997; Davidson, 2004) . Balkan and Vietnam war veterans also show a decreased fronto-cortical benzodiazepine recognition site binding (Bremner et al., 2000; Geuze et al., 2008) . Of note, we found a lack of sedative (Pinna et al., 2006b ) and anxiolytic (Pinna G, unpublished observation) activity of diazepam and zolpidem in mice that were socially isolated for up to 4 weeks. The effect seemed to be mediated by changes in the expression of several GABA A receptor subunits, including a decrease of a1, a2, and g2, and an increase of a4 and a5 subunits (Pinna et al., 2006b) . These changes were accompanied by a decrease of [ 3 H]flumazenil binding to hippocampal synaptic membranes (Pinna et al., 2006b ). These results are in agreement with an earlier study, which reported brain benzodiazepine receptor changes in socially isolated mice (Essman and Valzelli, 1981) .
In summary, although the initial mechanism whereby social isolation in mice decreases, corticolimbic allopregnanolone levels may be different from the mechanism that decreases CSF allopregnanolone levels after traumatic events in PTSD patients, the behavioral effects of protracted corticolimbic allopregnanolone deficiency and the resulting GABAergic neurotransmission deficit in socially isolated mice resemble those observed in PTSD patients. Selective brain steroidogenic stimulants upregulate corticolimbic allopregnanolone levels and reverse behavioral deficits in socially isolated mice As discussed earlier, fluoxetine and fluvoxamine may improve depressive symptoms by upregulating brain allopregnanolone levels (Uzunova et al., 1998) . Furthermore, fluoxetine and paroxetine were shown to increase allopregnanolone content in the olfactory bulb and frontal cortex in rodents (Uzunov et al., 1996; Matsumoto et al., 1999) . With these findings in mind, we designed several studies to show, in a mouse model of PTSD, that the beneficial behavioral effects of SSRIs were indeed exerted by the neurosteroidogenic upregulation of corticolimbic allopregnanolone levels, rather than their intrinsic activity as 5-HT reuptake inhibitors.
As fluoxetine is an S and R racemic mixture that is metabolized into S or R-norfluoxetine (Potts and Parli, 1992) , SBSS effects on a mouse model of PTSD Pinna 443 we tested the ability of these drugs to stereospecifically upregulate corticolimbic allopregnanolone content or to inhibit 5-HT reuptake. Part of this hypothesis was that fluoxetine and norfluoxetine stereoisomer doses that change corticolimbic allopregnanolone content may differ from those that inhibit 5-HT reuptake. Table 1 and Fig. 3 show that fluoxetine and norfluoxetine, in submicromolar doses and in a stereospecific manner, reverse the decrease of corticolimbic allopregnanolone levels caused by social isolation. The S-stereoisomers of fluoxetine or norfluoxetine are several folds more potent than their respective R-stereoisomers (Fig. 3 and Table 1 ). S-norfluoxetine is about 5-fold more potent than S-fluoxetine. Importantly, the effective concentrations (EC 50 s) of S-fluoxetine and S-norfluoxetine that normalize the brain allopregnanolone content are 10-(S-fluoxetine) and 50-fold (S-norfluoxetine) lower than their respective EC 50s needed to inhibit 5-HT reuptake (Table 1 and Fig. 4 ).
The possibility that fluoxetine and its congeners could abolish the behavioral deficits associated with protracted social isolation by increasing brain allopregnanolone content, rather than by a mechanism involving 5-HT reuptake inhibition, was tested by measuring aggressiveness and changes in sedation induced by pentobarbital in socially isolated male mice. Fluoxetine dose dependently and stereospecifically normalized the duration of pentobarbital-induced sedation (Fig. 5) and reduced aggressiveness (Fig. 6) at the same doses that also normalized the downregulation of brain allopregnanolone content in socially isolated mice (Table 1) .
Similarly, the actions of norfluoxetine are stereospecific (S-norfluoxetine > R-norfluoxetine) and are about 3-fold more potent than fluoxetine, both in normalizing pentobarbital-induced sedation and in inhibiting the aggressive behavior induced by social isolation in male mice (Figs 5 and 6, and Table 1 ). These actions are paralleled by Table 1 Fluoxetine and norfluoxetine stereoisomers induce normalization of pentobarbital right reflex loss, reduce the duration of attacks against an intruder (aggression), and activate neurosteroidogenesis (allopregnanolone) at doses that fail to affect 5-HT reuptake ]5-HT reuptake measurement. Data represent the mean ± SEM of four to six mice socially isolated for 4 weeks before testing. The EC 50 were calculated from dose-response curves analyzed by the 'quantal dose-response: probits test' (Tallarida and Murray, 1987) equipped with a statistical package. Statistical comparisons among the different EC 50 values were performed by using the COHORT package (Cohort Software, Monterey California, USA). For details see Pinna et al. (2003a Pinna et al. ( , 2004 Pinna et al. ( , 2009 . 5-HT, serotonin; EC 50 , effective concentration; PTB-RRL, pentobarbital right reflex loss. *P < 0.01 when S-fluoxetine is compared with R-fluoxetine. **P < 0.001 when S-norfluoxetine is compared with R-norfluoxetine and S-fluoxetine. Increase of allopregnanolone levels in the olfactory bulb (OB) of socially isolated (SI) mice after the treatment with fluoxetine (FLX) and norfluoxetine (NFLX) stereoisomers. R and S-FLX (a) and R and S-NFLX (b) were given 30 min before allopregnanolone determination. P values are from the comparison of R and S-FLX-treated and R and S-NFLX-treated SI mice with vehicle-treated SI mice. *P < 0.05, **P < 0.01. Each value is the mean ± SEM of six mice. GH, group-housed mice; i.p., intraperitoneal. For details see Pinna et al. (2004) .
increases in corticolimbic allopregnanolone levels ( Fig. 3 and Table 1 ). The potency of S-norfluoxetine in normalizing the duration of pentobarbital-induced sedation and inhibiting aggression is 7-fold higher than that of the R-isomer (Table 1) . At these low doses, S-norfluoxetine efficiently normalized the exaggerated contextual fear-conditioning responses and anxiety-like behavior of socially isolated mice (Pinna et al., 2006a; Pibiri et al., 2008) .
Most importantly, this study also showed that the action of S-fluoxetine and S-norfluoxetine on pentobarbitalinduced sedation, the inhibition of aggression, or the normalization of corticolimbic allopregnanolone content cannot be related to their intrinsic SSRI activity. In fact: (i) the EC 50 of S-fluoxetine and S-norfluoxetine in normalizing pentobarbital-induced sedation, reducing aggression, and upregulating corticolimbic allopregnanolone levels in socially isolated mice are at least 10-50 . P values are from the comparison of FLX or NFLX-treated SI mice with vehicle-treated SI mice. *P < 0.05, **P < 0.01. Each value is the mean ± SEM of six to eight mice. GH, grouphoused mice. For details see Pinna et al. (2004) .
times lower than the EC 50 required to inhibit 5-HT reuptake (Table 1) and (ii) SSRI activity of S or R-fluoxetine and of S or R-norfluoxetine is devoid of stereospecificity (Table 1 ). In addition to the direct evidence provided by the above-detailed experiments, we have found indirect evidence that favors a selective brain steroidogenic stimulant (SBSS) role of the so-called 'SSRI', fluoxetine and norfluoxetine: (i) doses of imipramine that inhibit 5-HT reuptake fail to reduce aggression and to normalize the decreased corticolimbic allopregnanolone levels of socially isolated mice (Pinna et al., 2003a) , (ii) the antidepressant tianeptine, which acts on the glutamatergic system (McEwen et al., 2010) and is devoid of SSRI activity (Mennini et al., 1987) , also increased olfactory bulb allopregnanolone levels and decreased social isolation-induced aggression (Pinna et al., 2003b) , and (iii) P-chlorophenylalanine, in doses that reduced brain 5-HT levels by more than 80%, failed to prevent the action of fluoxetine on pentobarbital-induced sedation or on the increase of corticolimbic allopregnanolone content in socially isolated mice (Matsumoto et al., 1999) .
Hence, the 5-HT reuptake inhibition elicited by the S stereoisomers of fluoxetine and norfluoxetine is not operative in decreasing social isolation-induced aggression, potentiating pentobarbital-induced sedation, or normalizating downregulated corticolimbic allopregnanolone levels.
In accord with these results are findings obtained using the olfactory bulbectomized rat model of depression, in which allopregnanolone levels are downregulated in several corticolimbic structures (Uzunova et al., 2003 (Uzunova et al., , reviewed in 2006 . In these studies, a number of antidepressants, including fluoxetine, sertraline, and venlafaxine were found to potently reverse the decline of allopregnanolone content induced by bilateral bulbectomy in selected cerebrocortical regions (Uzunova et al., 2004) .
Mechanisms by which neurosteroidogenic antidepressants increase neurosteroids
The mechanism by which fluoxetine and norfluoxetine or other neurosteroidogenic antidepressants (i.e. paroxetine, fluvoxamine, sertraline) increase corticolimbic allopregnanolone levels in socially isolated mice or in bulbectomized rats remains unclear. The high potency and stereospecificity of these drugs in reducing behavioral deficits and in normalizing brain allopregnanolone content suggest that they may affect specific targets for neurosteroidogenesis.
The finding that protracted social isolation affects the expression of 5a-RI in corticolimbic structures, but fails to change the expression of 3a-HSD Agis-Balboa et al., 2007; Pibiri et al., 2008) , and that brain progesterone levels fail to change in socially isolated mice suggests that a mechanism involving 5a-RI is responsible for the decrease of corticolimbic allopregnanolone content. This is additionally supported by the fact that 5a-RI is the rate-limiting step-enzyme in allopregnanolone biosynthesis from progesterone . Hence, these data point to a possible fluoxetine and norfluoxetine-mediated upregulation of corticolimbic allopregnanolone levels by a direct action on 5a-RI.
Studies in vitro using recombinant rat 5a-RI showed that fluoxetine, paroxetine, and sertraline in concentrations as high as 50 mmol/l failed to activate 5a-RI (Griffin and Mellon, 1999) . However, they do directly activate 3a-HSD by decreasing its K m for 5a-DHP by 100-fold, and thereby facilitate the reduction of 5a-DHP into allopregnanolone (Griffin and Mellon, 1999) . From studies performed in socially isolated mice the doses of fluoxetine and Norfluoxetine * * * * * * * * * * * norfluoxetine that cause a rapid increase in brain allopregnanolone levels reach brain concentrations in the low nmol/l range, whereas the fluoxetine concentrations that directly activate 3a-HSD in vitro are in the mmol/l range (Griffin and Mellon, 1999) . Studies conducted by Uzunov et al. (1996) showed that treatment with fluoxetine failed to alter allopregnanolone levels in plasma and that this drug selectively activated neurosteroidogenesis independently of peripheral steroidogenic input. The levels of 5a-DHP were unchanged or even decreased after fluoxetine and paroxetine administration, which supports the activation of 3a-HSD as the responsible mechanism (Uzunov et al., 1996) . Furthermore, the hypothesis that neurosteroidogenic antidepressants may activate 3a-HSD is suggested by experiments in which preincubation with fluoxetine accelerated the rate of accumulation of allopregnanolone after the incubation of brain slices with 5a-DHP (Uzunov et al. 1996) . Unfortunately, the hypothesis that fluoxetine and paroxetine directly activate 3a-HSD has not been supported by more recent results (Trauger et al., 2002) . It is feasible, however, that the kinetics of 5a-RI and/or 3a-HSD may be altered in socially isolated mice, and that these enzymes become susceptible to neurosteroidogenic antidepressants. This is suggested by the finding that low doses of the S isomers of fluoxetine or norfluoxetine increase the levels of allopregnanolone in socially isolated mice, but the same doses fail to change the corticolimbic levels of allopregnanolone in group-housed mice (Matsumoto et al., 1999; Pinna et al., 2003a) . These observations require further investigation at the molecular enzymatic level. For example, it is important to determine whether these neurosteroidogenic agents affect 5a-RI and/or 3a-HSD activity by changing the affinity for substrate or co-factor. Although brain progesterone levels are not affected by fluoxetine administration in group-housed or socially isolated mice (Matsumoto et al., 1999) , these drugs may still activate neurosteroidogenesis by a specific mechanism upstream from progesterone. For instance, an interaction with mitochondrial benzodiazepine (mBZD) receptors with the polypeptide diazepam binding inhibitor that binds to mBZD receptors and activates steroidogenesis (Costa and Guidotti, 1991) or with the expression of the steroidogenic acute regulatory protein that transfers cholesterol to mBZD receptors (Artemenko et al., 2001 , Bose et al., 2002 is conceivable. Hence, among drugs that selectively stimulate neurosteroid biosynthesis and are devoid of intrinsic SSRI activity, one may consider agonists of 'mBZD receptors', such as the indoleacetamide derivatives FGIN 1-27 and congeners (Romeo et al., 1992; Auta et al., 1993) .
It cannot be excluded that fluoxetine and congeners could also change levels of enzyme expression by playing a role in the epigenetic regulation of 5a-RI operative during social isolation. Evidence for the epigenetic regulation of key steroidogenic enzymes is increasing (reviewed in Martinez-Arguelles and Papadopoulos, 2010). The 5 0 upstream region of rat 5a-RI includes all the features of CpG islands and contains several potential binding sites for the transcription factor Sp1 (Safe and Kim, 2004; Chang and Chen, 2005; Chen et al., 2007) . Sp1 is involved in the epigenetic control of the promoter activity regulating chromatin remodeling and favoring the propagation of methylation-free islands on gene promoters (Blanchard et al., 2007) . Thus, the expression of 5a-RI could also be regulated through an epigenetic regulation of promoter hypermethylation that may trigger 5a-RI mRNA downregulation after long-term social isolation. In favor of this hypothesis are data showing a significant increase in the expression levels of fronto-cortical DNA methyltransferase-1 mRNA in socially isolated mice (Tueting et al., 2008) . This finding suggests that social isolation may induce hypermethylation of the 5a-RI promoter and thereby downregulate 5a-RI expression and allopregnanolone levels. Therefore, it would be of interest to evaluate whether fluoxetine and norfluoxetine, either alone or in combination with inhibitors of DNA methyltransferase-1 Kundakovic et al., 2007) or DNA-demethylase inducers (Tremolizzo et al., 2005; Dong et al., 2007; Costa et al., 2009) including valproate, reverse the downregulation of social isolationinduced 5a-RI expression by an epigenetic mechanism. Valproate in combination with antipsychotics is currently being tested in clinical trials to treat psychiatric illness, such as schizophrenia, bipolar disorder, depression, and drug addiction (Tsankova et al., 2007; Guidotti et al., 2009) . Such studies are important in the treatment of depression and PTSD because in these psychiatric disorders, allopregnanolone brain levels are downregulated (Uzunova et al., 1998; Rasmusson et al., 2006) , probably because 5a-RI and/or 3a-HSD expression are epigenetically downregulated (Agis-Balboa et al., 2010) . Although the precise mechanism by which fluoxetine and norfluoxetine induce neurosteroidogenic effects in socially isolated mice at low nmol/l doses is unclear, studies involving neurosteroidogenic agents may help in the treatment of psychiatric disorders, including PTSD.
Conclusion
In the treatment of psychiatric disorders associated with GABAergic neurotransmission dysfunction mediated by a downregulation of brain allopregnanolone expression, such as in PTSD, the use of SBSSs seems to be the best selective and efficacious therapeutic strategy.
As reported above, the pharmacological spectrum of allopregnanolone as an allosteric modulator of GABA at GABA A receptors is broader than that of benzodiazepines, which fail to modulate GABA A receptors containing a4 and a6 subunits. The efficacy of allopregnanolone is expressed widely in several subtypes of GABA A receptors for doses in the low nmolar range. Hence, selective stimulation of allopregnanolone biosynthesis may avoid the therapeutic hindrances caused by GABA A receptors formed with altered subunit composition, such as may occur in stress-related psychiatric disorders (reviewed in Maguire and Mody, 2009 ).
Importantly, owing to the brain region-specific and neuron-specific expression of 5a-RI and 3a-HSD, the action of SBSSs on neurosteroid biosynthesis targets specific brain structures and is neuron-specific. Hence, SBSSs, including S-norfluoxetine, may be devoid of the unwanted side-effects that may be caused by a 'neurosteroid replacement therapy' with direct systemic administration of allopregnanolone and congeners (Phillipps, 1975; Gee et al., 1988; Smith et al., 1998; Reddy and Rogawski, 2000; Reddy and Woodward, 2004) .
Understanding the mechanism(s) whereby SBSSs increase corticolimbic allopregnanolone bioavailability and normalize stress-related behavioral symptoms may reveal a pharmacological target with important consequences in future drug development for the improvement of the behavioral symptoms of PTSD.
